Advertisement

Topics

Case report of the successful use of Mirena levonorgestrel intrauterine system in a patient with didelphys uterus and obstructed hemivagina.

07:00 EST 8th December 2018 | BioPortfolio

Summary of "Case report of the successful use of Mirena levonorgestrel intrauterine system in a patient with didelphys uterus and obstructed hemivagina."

The Mirena levonorgestrel intrauterine system (IUS) is frequently used for menstrual suppression in adolescents with special needs. However, the presence of a uterine anomaly is generally considered a contraindication to IUS insertion, thereby excluding a potentially highly effective option for this patient population.

Affiliation

Journal Details

This article was published in the following journal.

Name: Journal of pediatric and adolescent gynecology
ISSN: 1873-4332
Pages:

Links

DeepDyve research library

PubMed Articles [29445 Associated PubMed Articles listed on BioPortfolio]

Comparison of combined bipolar radiofrequency impedance-controlled endometrial ablation with levonorgestrel intrauterine system versus bipolar radiofrequency endometrial ablation alone in women with abnormal uterine bleeding.

This study aims to evaluate the efficacy of the combination of bipolar radiofrequency impedance-controlled endometrial ablation (NovaSure) and levonorgestrel intrauterine system (LNG-IUS, Mirena) plac...

Tamoxifen for the prevention of unscheduled bleeding in new users of the Levonorgestrel 52mg intrauterine system: a randomized controlled trial.

To determine if a course of oral tamoxifen initiated following placement of a levonorgestrel 52mg intrauterine system (IUS) reduces bleeding/spotting days over 30days.

Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy.

The objective was to investigate the Pearl index for ectopic pregnancy in women using levonorgestrel intrauterine system (LNG-IUS) at time of conception.

Bleeding and spotting with the levonorgestrel 13.5mg intrauterine system: the impact of insertion timing.

To assess the impact of early versus late menstrual cycle insertion on bleeding/spotting in the 90days following levonorgestrel (LNG) 13.5mg intrauterine system (IUS) insertion.

Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system.

To determine the long-term effects of using the levonorgestrel-releasing intrauterine system (LNG-IUS) to treat symptomatic adenomyosis.

Clinical Trials [11898 Associated Clinical Trials listed on BioPortfolio]

Pretreatment With Mifepristone Prior to Mirena Insertion

Hypothesis: Pretreatment with mifeprsitone prior to Mirena placement will induce amenorrhea and reduce bleeding irrregularities during the initial months of Mirena use.

LNG-IUS at 2 Weeks Postpartum

This is a study of 50 postpartum women interested in having the Mirena® LNG-IUS placed for contraception. The Mirena® is an FDA approved intrauterine contraceptive device that provides c...

Bleeding Pattern Difference Between Levonorgestrel Intrauterine System (LNG-IUS) and Copper Intrauterine Devices (IUDs) Immediately Inserted After Abortion

To observe the bleeding patterns of post-abortion immediate insertion of IUS compared to Cu-IUD over the first 6 months.

Mirena Observational Program

Mirena is used for long-term in Kazakhstan, and in our observational program we would like to study patients distribution per indications of Mirena, and also patient compliance within a ye...

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who req...

Medical and Biotech [MESH] Definitions

A system for classifying patient care by relating common characteristics such as diagnosis, treatment, and age to an expected consumption of hospital resources and length of stay. Its purpose is to provide a framework for specifying case mix and to reduce hospital costs and reimbursements and it forms the cornerstone of the prospective payment system.

Spontaneous loss of INTRAUTERINE DEVICES from the UTERUS.

Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.

The shifting in position or location of an INTRAUTERINE DEVICE from its original placement.

Intrauterine devices that release contraceptive agents.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article